廣瀬 雄一 ひろせ ゆういち 先生

来歴等

略歴

1987年　慶應義塾大学医学部卒業
1987年　慶應義塾大学病院研修医(外科学教室)
1988年　済生会神奈川県病院脳神経外科
1989年　足利赤十字病院脳神経外科
1990年　慶應義塾大学外科学教室(脳神経外科)助手
1993年　国立精神神経センター神経研究所流動研究員
1995年　足利赤十字病院脳神経外科
1998年　米国カリフォルニア大学サンフランシスコ校脳神経外科
2003年　慶應義塾大学外科学教室(脳神経外科)助手
2005年　慶應義塾大学外科学教室(脳神経外科)講師
2006年　藤田保健衛生大学（現・藤田医科大学）脳神経外科助教授
2010年　藤田保健衛生大学（現・藤田医科大学）脳神経外科主任教授
2013年　藤田保健衛生大学病院（現・藤田医科大学病院）　副院長

論文

(代表論文)
●Hattori N, Hirose Y, Sasaki H, Nakae S, Hayashi S, Ohba S, Adachi K, Hayashi T, Nishiyama Y, Hasegawa M, Abe M. WHO grade II-III astrocytomas consist of genetically distinct tumor lineages. Cancer Sci. 107 (8): 1159-1164, 2016
●Ohba S, Hirose Y. Biological significance of mutant isocitrate dehydrogenase 1 and 2 in gliomagenesis. Neurol Med Chir (Tokyo) 56(4):170-179, 2016.
●Nakae S, Sasaki H, Hayashi S, Hattori N, Kumon M, Nishiyama Y, Adachi K, Nagahisa S, Hayashi T, Inamasu J, Abe M, Hasegawa M, Hirose Y. PCR-Based Simple Subgrouping Is Validated for Classification of Gliomas and Defines Negative Prognostic Copy Number Aberrations in IDH Mutant Gliomas. PLoS One. 2015 Nov 11;10(11):e0142750.
●Hayashi S, Sasaki H, Kimura T, Abe T, Nakamura T, Kitamura Y, Miwa T, Kameyama K, Hirose Y, Yoshida K. Molecular–genetic and clinical characteristics of gliomas with astrocytic appearance and total 1p19q loss in a single institutional consecutive cohort. Oncotarget 6(18): 1587-1581, 2015
●Sasaki H, Hirose Y, Yazaki T, Kitamura Y, Katayama M, Kimura T, Fujiwara H, Toda M, Ohira T, Yoshida K. Upfront chemotherapy and subsequent resection for molecularly defined gliomas. J Neurooncol. 124(1): 127-135, 2015.
●Nishiyama Y, Sasaki H, Nagahisa S, Adachi K, Hayashi T, Yoshida K, Kawase T, Hattori N, Murayama K, Abe M, Hasegawa M, Katada K, Hirose Y. Radiological features of supratentorial gliomas are associated with their genetic aberrations Neurosurgical Review 37(2):291-300, 2014
●Hirose Y, Sasaki H, Abe M, Hattori N, Adachi K, NishiyamaY, Nagahisa S, Hayashi T, Hasegawa M, Yoshida K. Subgrouping of gliomas based on genetic profiles. Brain Tumor Pathology 30(4): 203-208, 2013
●Nagahisa S, Watabe T, Sasaki H, Nishiyama Y, Hayashi T, Hasegawa M, Hirose Y. Surgical navigation-assisted endoscope biopsy is feasible for safe and reliable diagnosis of unresectable solid brain tumors. Neurosurgical Review 36(4): 595-601, 3013
●Hayashi T, Adachi K, Ohba S, Hirose Y. The Cdk inhibitor flavopiridol enhances temozolomide-induced cytotoxicity in human glioma cells. J Neurooncol 115(2): 169-178, 2013
●Kanai R, Rabkin SD, Yip S, Sgubin D, Zaupa CM, Hirose Y, Louis DN, Wakimoto H, Martuza RL. Oncolytic virus-mediated manipulation of DNA damage responses: synergy with chemotherapy in killing glioblastoma stem cells. J Natl Cancer Inst 104 (1): 42-55, 2012
●Hayashi T, Inamasu J, Kanai R, Sasaki H, Shinoda, J, Hirose Y. Clinical, histological, and genetic features of fourth ventricle ependymoma in the elderly. Neurologia medico-chirurgica 52(8): 611-616, 2012
●Hirose Y, Sasaki H, Miwa T, Ohba S, Ikeda E, Abe M, Ikeda S, Kobayashi M, Kawase T, Hasegawa M, Yoshida K. Whole genome analysis from microdissected tissue revealed adult supratentorial grade II-III gliomas are divided into clinically relevant subgroups by genetic profile. Neurosurgery 69: 376-390, 2011
●Ezaki T, Sasaki H, Hirose Y, Miwa T, Yoshida K, Kawase T: Molecular characteristics of pediatric non-ependymal, non-pilocytic gliomas associated with resistance to temozolomide. Molecular Medicine Reports 4: 1101-1105, 2011
●Miwa T, Hirose Y, Sasaki H, Ezaki T, Yoshida K, Kawase T. Single-copy gain of chromosome 1q is a negative prognostic marker in pediatric nonependymal, nonpilocytic gliomas. Neurosurgery. 68: 206-212, 2011
●Mutou J, Hirose Y, Ikeda E, Yoshida K, Nakazato Y, Kawase T. Malignant brain tumor with rhabdoid features in an adult. Neurologia medico-chirurgica (Tokyo) 51(6): 449-454, 2011
●Ohba S, Hirose Y, Yoshida K, Yazaki T, Kawase T. Inhibition of 90-kD heat shock protein potentiates the cytotoxicity of chemotherapeutic agents in human glioma cells. Journal of Neurosurgery. 112: 33-42, 2010
●Ohba S, Yoshida K, Hirose Y, Ikeda E, Kawase T. Meningioma of the cerebellopontine angle in identical twins: a case report. Journal of Neuro-oncology. 98: 411-415, 2010
●Peev NA, Hirose Y, Hirai T, Nishiyama Y, Nagahisa S, Kannno T, Sano H. Delayed surgical resections of brain metastases after gamma knife radiosurgery. Neurosurgical Review 33: 349-357, 2010
●Miwa T, Hirose Y, Sasaki H, Ikeda E, Yoshida K, Kawase T. Genetic characterization of adult infratentorial gliomas. Journal of Neuro-oncology 91: 251-255, 2009
●Ohba S, Yoshida K, Hirose Y, Ikeda E, Nakazato Y, Kawase T A cerebral tumor with extensive rhabdoid features and favorable prognosis. Journal of Neurosurgery 111: 492-496, 2009
●Ohba S, Yoshida K, Hirose Y, Ikeda E, Kawase T. Early malignant transformation of a petroclival meningothelial meningioma. Neurosurgical Review 32: 495-499 2009
●Ohba S, Hirose Y, Kawase T, Sano H. Inhibition of c-Jun N-terminal kinase enhances temozolomide-induced cytotoxicity in human glioma cells. Journal of Neuro-oncology 95(3):307-316, 2009
●Ohba S, Yoshida K, Hirose Y, Ikeda E, Kawase T. A supratentorial primitive neuroectodermal tumor in an adult: A case report and review of the literature. Journal of Neuro-oncology 86: 217-224, 2008
●Kanai R, Tomita H, Hirose Y, Ohba S, Goldman S, Okano H, Kawase T, Yazaki T. Augmented therapeutic efficacy for the treatment of malignant glioma by an oncolytic HSV-1 mutant expressing ICP34.5 under the transcriptional control of Musashi1 promoter. Human Gene Therapy 18: 63-73, 2007
●Ware ML. Hirose Y, Scheithauer BW, Yeh R-F, Mayo MC, Smith JS, Chang S, Cha S, Tihan T, Feuerstein BG. Genetic aberrations in gliomatosis cerebri. Neurosurgery 60: 150-158, 2007
●Takahashi S, Hirose Y, Fukaya R, Kawase K. Malignant glioma with DNA copy number gain on chromosomal arm 1q presented good response to chemotherapy. Journal of Neurosurgery 106: 488-494, 2007
●Mikami S, Hirose Y, Yoshida K, Kawase T, Ohnishi A, Nagashima K, Mukai M, Okada Y, Ikeda E. Predominant expression of OLIG2 over ID2 in oligodendroglial tumors. Virchows Arch 450: 575-584, 2007
●Hirose Y, Yoshida K. Chromosomal abnormalities subdivide neuroepithelial tumors into clinically relevant groups. Keio J Med 55:52-8, 2006
●Hirose Y, Katayama M, Mirzoeba OK, Berger MS, Pieper RO. Akt activation suppresses Chk2-mediated, methylating agent-induced G2 arrest and protects from temozolomide-induced mitotic catastrophe and cellular senescence. Cancer Research 65: 4861-4869, 2005
●Hirose Y, Katayama M, Berger MS, Pieper RO. Cooperative function of Chk1 and p38 pathways in activating G2 arrest following exposure to temozolomide. Journal of Neurosurgery 100: 1060-1065, 2004
●Hirose Y, Katayama M, Stokoe D, Haas-Kogan DA, Berger MS, Pieper RO. The p38 mitogen-activated protein kinase pathway links the DNA mismatch repair system to the G2 checkpoint and to resistance to chemotherapeutic DNA-methylating agents. Molecular and Cellular Biology 23: 8306-8315, 2003
●Hirose Y, Kreklau EL, Erickson LC, Berger MS, Pieper RO. Delayed repletion of O6-methylguanine-DNA methyltransferase resulting in failure to protect the human glioblastoma cell line SF767 from temozolomide-induced cytotoxicity Journal of Neurosurgery 98: 591-598, 2003
●Hirose Y, Aldape KD, Chang S, Lamborn K, Berger MS, Feuerstein BG. Grade II astrocytomas are subgrouped by chromosome aberrations. Cancer Genetics Cytogenetics 142: 1-7, 2003
●Hirose Y, Aldape K, Takahashi M, Berger MS, Feuerstein BG. Tissue microdisssection and degenerate oligonucleotide primed-polymerase chain reaction (DOP-PCR) is an effective method to analyze genetic aberrations in invasive tumors. Journal of Molecular Diagnostics 3: 62-67, 2001
●Hirose Y, Berger MS, Pieper RO. Abrogation of the Chk1-mediated G(2) checkpoint pathway potentiates temozolomide-induced toxicity in a p53-independent manner in human glioblastoma cells Cancer Research 61: 5843-5849, 2001
●Hirose Y, Berger MS, Pieper RO. p53 effects both the duration of G2/M arrest and the fate of temozolomide-treated human glioblastoma cells. Cancer Research 61: 47-63, 2001
●Hirose Y, Aldape K, Bollen A, James CD, Brat D, Lamborn K, Berger M, Feuerstein BG. Chromosomal abnormalities subdivide ependymal tumors into clinically relevant groups. American Journal of Pathology 158: 1137-1143, 2001
●Sonoda Y, Ozawa T, Hirose Y, Aldape KD, McMahon M, Berger MS, Pieper RO. Formation of intracranial tumors by genetically modified human astrocytes defines four pathways critical in the development of human anaplastic astrocytoma. Cancer Research 61: 4956-4960, 2001
●Brat DJ, Hirose Y, Cohen KJ, Feuerstein BG, Burger PC. Astroblastoma: clinicopathologic features and chromosomal abnormalities defined by comparative genomic hybridization. Brain Patholology 10: 342-345, 2000
●Hirose Y, Sagoh M, Mayanagi K, Murakami H. Abducens nerve palsy caused by basilar impression associated with atlanto-occipital assimilation. Neurologia medico-chirurgica (Tokyo) 38: 363-366, 1998
●Hirose Y, Kojima M, Sagoh M, Murakami H, Yoshida K, Shimazaki K, Kawase T. Immunohistochemical examination of c-Met protein expression in astrocytic tumors. Acta Neuropathologica (Berlin) 95: 345-351, 1998